Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received an average recommendation of “Buy” from the twenty-one analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seventeen have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $180.77.
A number of research firms recently commented on JAZZ. TheStreet upgraded shares of Jazz Pharmaceuticals PLC from a “c+” rating to a “b-” rating in a report on Tuesday, March 28th. Piper Jaffray Companies set a $181.00 target price on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Saturday, April 8th. Leerink Swann set a $179.00 target price on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Thursday, April 27th. Sanford C. Bernstein set a $176.00 target price on shares of Jazz Pharmaceuticals PLC and gave the stock a “market perform” rating in a report on Monday, May 22nd. Finally, Vetr upgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 target price on the stock in a report on Tuesday, June 6th.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 0.21% during mid-day trading on Friday, hitting $158.46. 390,849 shares of the stock traded hands. The stock has a 50 day moving average price of $152.09 and a 200 day moving average price of $135.76. The firm has a market cap of $9.51 billion, a PE ratio of 23.94 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing analysts’ consensus estimates of $1.42 by $0.01. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The business had revenue of $376.10 million during the quarter, compared to the consensus estimate of $376.58 million. During the same quarter in the previous year, the firm earned $2.26 earnings per share. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. On average, analysts expect that Jazz Pharmaceuticals PLC will post $11.00 earnings per share for the current fiscal year.
In related news, SVP Karen J. Wilson sold 1,275 shares of the business’s stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $160.00, for a total transaction of $204,000.00. Following the transaction, the senior vice president now directly owns 21,133 shares of the company’s stock, valued at $3,381,280. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 11th. The shares were sold at an average price of $152.12, for a total transaction of $152,120.00. Following the transaction, the chief executive officer now directly owns 308,491 shares in the company, valued at $46,927,650.92. The disclosure for this sale can be found here. Insiders have sold 54,333 shares of company stock worth $8,345,824 over the last ninety days. 4.30% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Envestnet Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares during the last quarter. World Asset Management Inc bought a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $205,000. Bridges Investment Management Inc. bought a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $208,000. Private Advisor Group LLC bought a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $215,000. Finally, Logan Capital Management Inc. bought a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $223,000. 86.34% of the stock is currently owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/jazz-pharmaceuticals-plc-jazz-receives-180-77-consensus-target-price-from-brokerages/1941476.html
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.